Free Access
Fetal Diagn Ther 2012;31:141–146
(DOI:10.1159/000336662)

Early Administration of Low-Dose Aspirin for the Prevention of Preterm and Term Preeclampsia: A Systematic Review and Meta-Analysis

Roberge S.a · Villa P.d · Nicolaides K.f · Giguère Y.c · Vainio M.e · Bakthi A.g · Ebrashy A.h · Bujold E.a, b
aDepartment of Social and Preventive Medicine, bDepartment of Obstetrics and Gynecology, and cDepartment of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Quebec City, Que., Canada; dDepartment of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, and eKanta-Häme Central Hospital, Hämeenlinna, Finland; fHarris Birthright Research Centre of Fetal Medicine, King’s College Hospital, London, UK; gHassiba Ben Bouali Clinic, Centre Hospitalo-Universitaire de Blida, Blida, Algeria; hFetal Medicine Unit and Department of Obstetrics and Gynecology, Cairo University, Cairo, Egypt
email Corresponding Author


 Outline


 goto top of outline Key Words

  • Preeclampsia
  • Aspirin
  • Preterm

 goto top of outline Abstract

Objective: To compare the effect of early administration of aspirin on the risk of preterm and term preeclampsia. Method: A systematic review and meta-analysis of randomized controlled trials were performed. Women who were randomized to low-dose aspirin or placebo/no treatment at or before 16 weeks of gestation were included. The outcomes of interest were preterm preeclampsia (delivery <37 weeks) and term preeclampsia. Pooled relative risks (RR) with their 95% confidence intervals (CI) were computed. Results: The search identified 7,941 citations but only five trials on a combined total of 556 women fulfilled the inclusion criteria. When compared to controls, aspirin initiated ≤16 weeks of gestation was associated with a major reduction of the risk of preterm preeclampsia (RR 0.11, 95% CI 0.04–0.33) but had no significant effect on term preeclampsia (RR 0.98, 95% CI 0.42–2.33). Conclusion: Low-dose aspirin administrated at or before 16 weeks of gestation reduces the risk of preterm but not term preeclampsia.

Copyright © 2012 S. Karger AG, Basel


goto top of outline Introduction

Preeclampsia, which affects about 2–8% of pregnancies, is thought to be the consequence of impaired trophoblastic invasion of the maternal spiral arteries [1,2]. There is evolving evidence that both the degree of impaired placentation and the incidence of adverse fetal and maternal short- and long-term consequences of preeclampsia are inversely related to the gestational age at onset of the disease [3,4,5,6,7,8,9].

There is extensive evidence from randomized studies that the prophylactic use of low-dose aspirin is associated with 10% reduction in the prevalence of preeclampsia in women at risk of this pregnancy complication [10]. However, the effectiveness of aspirin may be related to the onset of treatment. Bujold et al. [11] reported that when low-dose aspirin is started after 16 weeks of gestation there is no significant decrease in the risk of the disease, whereas with treatment starting at or before 16 weeks there is a halving in the risk. This finding suggests that early administration of aspirin may reduce the risk of preeclampsia, possibly by improving placentation. It is therefore possible that early-onset use of aspirin may be more effective in preventing preterm than term preeclampsia.

The aim of this systematic review and meta-analysis of randomized studies that evaluated the benefits of low-dose aspirin started at or before 16 weeks of gestation is to examine the effects on the risk of preterm and term preeclampsia in a population of women at risk of preeclampsia.

 

goto top of outline Method

goto top of outline Sources

Relevant citations were extracted from Embase, PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science from 1965 to October 2011. Keywords and MeSH terms were combined to generate lists of studies: ‘aspirin’, ‘antiplatelet’, ‘salicy*’, ‘ASA’, ‘pregnancy-complication’, ‘hypertens*’, ‘blood press*’, ‘*eclamp*’, ‘PIH’, ‘toxaemi*’, ‘IUGR’. No language restriction was imposed. The first reviewer (S.R.) sorted all articles by citations and abstract for more detailed evaluation. The second sort was revised by two reviewers (S.R., E.B.) and all relevant trials were entirely reviewed by the same two reviewers. Quality and integrity of this review were validated with PRISMA: preferred reporting items for systematic reviews and meta-analyses [12].

goto top of outline Study Selection

Only prospective, randomized, controlled trials were included. The population in the studies involved pregnant women at risk of preeclampsia treated with low-dose aspirin at or before 16 weeks of gestation. No restrictions were applied to risk criteria for preeclampsia (table 1). Low-dose aspirin was defined as 50–150 mg of acetylsalicylic acid (ASA) daily, alone or in combination with <300 mg of dipyridamole, another antiplatelet agent. The control group had to be allocated to placebo or no treatment. Study quality was evaluated by using Cochrane Handbook Criteria for judging risk of bias tool, and studies with high risk of bias were considered for exclusion [13].

TAB01
Table 1. Characteristics of included studies

goto top of outline Outcomes Measures

The outcome measures were preterm preeclampsia (delivered before 37 completed weeks’ gestation) and term preeclampsia. The American College of Obstetricians and Gynecologists defines preeclampsia as blood pressure of 140 mm Hg systolic or higher or 90 mm Hg diastolic or higher that occurs after 20 weeks of gestation in a woman with previously normal blood pressure plus proteinuria, defined as urinary excretion of 0.3 g protein or higher in a 24-hour urine specimen or 2+ protein on dipstick [14]. However, as the definition of preeclampsia varies between countries, we accepted all similar definitions [15,16].

goto top of outline Statistical Analysis

All studies were combined and analyzed with Review Manager 5.0.25 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) software. Individual risk ratios (RR) were calculated for each study, and pooled for global analysis with 95% confidence intervals (CI). Analysis of preeclampsia was divided into preterm preeclampsia and term preeclampsia. Global RR was calculated according to DerSimonian and Laird random effect models in case of heterogeneity [17,18]. Heterogeneity between studies was analyzed with Higgins’ I2 and considered to be high over 50% [19]. The distribution of trials was examined with funnel plots to assess publication bias [20].

 

goto top of outline Results

The literature search identified 7,941 potentially eligible studies (fig. 1). Of these, only five studies on a combined total of 556 women were included in the final analysis because they fulfilled the three entry criteria: (1) treatment with aspirin or placebo initiated at or before 16 weeks of gestation, (2) information provided on preterm and term preeclampsia, and (3) judged for low-risk or unclear risk of bias. The control group received placebo in three of these studies and no treatment in two (table 1) [21,22,23,24,25].

FIG01
Fig. 1. Processes of selection of the articles.

We found that low-dose aspirin administered at or before 16 weeks of gestation was associated with a significant reduction in the risk of preterm preeclampsia, but not term preeclampsia (table 2; fig. 2, 3). A random model was used for both outcomes because of high heterogeneity between the included studies for at least one outcome; the heterogeneity for preterm preeclampsia was 0% and for term preeclampsia it was 54%. Analysis of the funnel plot was precluded because of the small number of included studies. According to Cochrane Handbook Criteria for judging risk of bias tool, the included studies were judged to have low or unclear risk of bias [13].

TAB02
Table 2. Relative risk of preterm and term preeclampsia associated with the use of low-dose aspirin at or before 16 weeks’ gestation

FIG02
Fig. 2. Forest plot of the effect of low-dose aspirin initiated at or before 16 weeks’ gestation on the risk of preterm preeclampsia.

FIG03
Fig. 3. Forest plot of the effect of low-dose aspirin initiated at or before 16 weeks’ gestation on the risk of term preeclampsia.

 

goto top of outline Discussion

This meta-analysis was restricted to randomized controlled trials which firstly examined the use of low-dose aspirin initiated at or before 16 weeks of gestation and secondly provided data on both outcome measures of interest: preterm preeclampsia, as defined by delivery of women with preeclampsia before 37 completed weeks of gestation, and term preeclampsia. The inclusion criteria were met by only five studies on a total of 556 patients. Nevertheless, the results demonstrate a major beneficial effect of low-dose aspirin prophylaxis started at or before 16 weeks of gestation in reducing preterm preeclampsia. In contrast, the use of aspirin was not associated with a significant reduction in the risk of term preeclampsia.

A meta-analysis of 31 trials on a combined total of 32, 217 pregnancies reported that use of low-dose aspirin was associated with a 10% reduction in the prevalence of both preeclampsia and delivery before 34 weeks’ gestation [10]. However, this study did not examine the differential effect of early initiation of treatment. In our previous meta-analysis we found that the effect of aspirin was substantially higher if treatment is initiated at or before 16 weeks rather than after this gestation [11]. The findings of our present study extend the results of the previous one by demonstrating that the use of aspirin starting at or before 16 weeks may be particularly effective in preventing severe preeclampsia requiring preterm delivery.

A major limitation of our meta-analysis is the small number of studies fulfilling the entry criteria. Moreover, the presence of heterogeneity for term preeclampsia suggests the presence of variance between included studies. However, the strength of the association and the great homogeneity for preterm preeclampsia suggests that the findings are likely to be valid. Nevertheless, the results require validation by major randomized studies in which the entry criterion would be high risk for preeclampsia identified by first-trimester screening and the outcome measures would be the risk of preeclampsia at a different gestational age, as well as the associated perinatal mortality and morbidity.

Preterm preeclampsia is more severe than term preeclampsia and is associated with a higher incidence of adverse maternal and perinatal consequences [3,4,5,6,7,8]. Our finding of a reduction in the risk of preterm preeclampsia by about 89% is compatible with the finding of the previous meta-analysis where the reduction in severe preeclampsia was about 91% (RR 0.09, 95% CI 0.02–0.37) [11]. Our finding is also in agreement with data of Beaufils et al. [26] who found strong benefits of low-dose aspirin initiated at 14–16 weeks for the prevention of severe preeclampsia and preeclampsia diagnosed before 37 weeks. Beaufils et al. [26] found that aspirin was associated with a reduction of severe preeclampsia (RR 0.07, 95% CI 0.00–1.25). We were not able to obtain the data for preeclampsia with delivery before 37 weeks for this study.

Pathological studies have shown that the prevalence of placental lesions in women with preeclampsia is inversely related to the gestational age at delivery [6,27]. Furthermore, epidemiological studies have reported that preterm preeclampsia is associated with low birth weight, whereas in term preeclampsia the birth weight is often normal or increased [28,29,30,31]. Studies investigating the use of Doppler ultrasound in the assessment of impedance to blood flow in the uterine arteries, as an indirect measure of impaired placentation, have demonstrated that the pulsatility index is increased mainly in preterm compared to term preeclampsia [32]. A multicenter screening study in more than 30,000 singleton pregnancies reported that the uterine artery pulsatility index at 22–24 weeks’ gestation was above the 95th percentile in 77% of women who developed preeclampsia requiring delivery before 34 weeks, in 36% of those delivering at 34–37 weeks and in 22% of those delivering at term [8].

In conclusion, our meta-analysis showed that the initiation of low-dose aspirin prophylaxis at or before 16 weeks’ gestation resulted in a 89% reduction of preeclampsia delivered before 37 weeks’ gestation, but had no effect on the risk of term preeclampsia. The most likely explanation for our findings is that early administration of low-dose aspirin improves placentation. Such an effect would result firstly in a reduction in the overall risk of the disease and secondly in a shift from early-onset severe disease requiring preterm delivery to a milder disease presenting at term. This hypothesis warrants to be tested in future large-scale randomized studies on the effect of low-dose aspirin in women with evidence of impaired placentation in early pregnancy [33,34,35].

 

goto top of outline Disclosure Statement

The authors have no conflicts of interest to disclose.


 goto top of outline References
  1. Geographic variation in the incidence of hypertension in pregnancy: World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy. Am J Obstet Gynecol 1988;158:80–83.
  2. Duley L: The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130–137.
  3. Witlin AG, Saade GR, Mattar F, Sibai BM: Predictors of neonatal outcome in women with severe preeclampsia or eclampsia between 24 and 33 weeks’ gestation. Am J Obstet Gynecol 2000;182:607–611.
  4. Irgens HU, Reisaeter L, Irgens LM, Lie RT: Long-term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 2001;323:1213–1217.
  5. Von Dadelszen P, Magee L, Krajden M, Alasaly K, Popovska V, Devarakonda R, Money D, Patrick D, Brunham R: Levels of antibodies against cytomegalovirus and Chlamydophila pneumoniae are increased in early onset pre-eclampsia. BJOG 2003;110:725–730.

    External Resources

  6. Moldenhauer JS, Stanek J, Warshak C, Khoury J, Sibai B: The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol 2003;189:1173–1177.
  7. Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD: Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. BJOG 2006;113:580–589.
  8. Yu CK, Khouri O, Onwudiwe N, Spiliopoulos Y, Nicolaides KH: Prediction of pre-eclampsia by uterine artery Doppler imaging: relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol 2008;31:310–313.
  9. Ogge G, Chaiworapongsa T, Romero R, Hussein Y, Kusanovic JP, Yeo L, Kim CJ, Hassan SS: Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. J Perinat Med 2011;39:641–652.

    External Resources

  10. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA: Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007;369:1791–1798.
  11. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguere Y: Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010;116:402–414.
  12. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
  13. Higgins J, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011.
  14. ACOG: Diagnosis and management of preeclampsia and eclampsia. Int J Gynecol Obstet 2002;77:67–75.
  15. Magee LA, Helewa M, Moutquin JM, von Dadelszen P: Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008;30(suppl):S1–S48.
  16. Sibai BM: Evaluation and management of severe preeclampsia before 34 weeks’ gestation. Am J Obstet Gynecol 2011;205:191–198.

    External Resources

  17. DerSimonian R, Laird N: Meta-Analysis in Clinical Trials. Controlled Clin Trials 1986;7:177–188.
  18. Chevalier P vDM, Vermeire E: Hétérogénité dans les synthèses méthodiques et méta-analyses. Minerva 2007;6:160.
  19. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003;327:557–560.
  20. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–634.
  21. August P, Helseth G, Edersheim T, Hutson J, Druzin M: Sustained release, low-dose aspirin ameliorates but does not prevent preeclampsia in a high risk population. Proceedings of 9th International Congress of the International Society for the Study of Hypertension, 1994. Sydney, Hypertension in Pregnancy, 1994, p 72.
  22. Bakhti A, Vaiman D: Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation. Hypertens Res 2011;34:1116–1120.
  23. Ebrashy A, Ibrahim M, Marzook A, Yousef D: Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14–16 weeks pregnancy: randomized controlled clinical trial. Croat Med J 2005;46:826–831.

    External Resources

  24. Vainio M, Kujansuu E, Iso-Mustajarvi M, Maenpaa J: Low-dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG 2002;109:161–167.
  25. Villa P, Taipale P, Räikkönen K, Hämäläi-nen E, Pesonen A, Kajantie E, Laivuori H: PREDO trial – acetylsalicylic acid in preventing pre-eclampsia in high-risk women. 17th ISSHP World Congress, Melbourne, October 2010. Pregnancy Hypertension 2010(suppl):1–41.
  26. Beaufils M, Uzan S, Donsimoni R, Colau JC: Prevention of pre-eclampsia by early antiplatelet therapy. Lancet 1985;1:840–842.
  27. Sebire NJ, Goldin RD, Regan L: Term preeclampsia is associated with minimal histopathological placental features regardless of clinical severity. J Obstet Gynaecol 2005;25:117–118.
  28. Vatten LJ, Skjaerven R: Is pre-eclampsia more than one disease? BJOG 2004;111:298–302.
  29. Xiong X, Demianczuk NN, Saunders LD, Wang FL, Fraser WD: Impact of preeclampsia and gestational hypertension on birth weight by gestational age. Am J Epidemiol 2002;155:203–209.
  30. Odegard RA, Vatten LJ, Nilsen ST, Salvesen KA, Austgulen R: Preeclampsia and fetal growth. Obstet Gynecol 2000;96:950–955.
  31. Xiao R, Sorensen TK, Williams MA, Luthy DA: Influence of pre-eclampsia on fetal growth. J Matern Fetal Neonatal Med 2003;13:157–162.
  32. Staboulidou I, Galindo A, Maiz N, Karagiannis G, Nicolaides KH: First-trimester uterine artery Doppler and serum pregnancy-associated plasma protein – a in preeclampsia and chromosomal defects. Fetal Diagn Ther 2009;25:336–339.
  33. Bujold E, Tapp S, Audibert F, Ferreira E, Forest JC, Rey E, Fraser WD, Chaillet N, Giguere Y: Prevention of adverse pregnancy outcomes with low-dose ASA in early pregnancy: new perspectives for future randomized trials. J Obstet Gynaecol Can 2011;33:480–483.
  34. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH: Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 2011;31:66–74.
  35. Nicolaides KH: Turning the pyramid of prenatal care. Fetal Diagn Ther 2011;29:183–196.

 goto top of outline Author Contacts

Emmanuel Bujold, MD, MSc
Jeanne et Jean-Louis Lévesque Perinatal Research Chair
Department of Obstetrics and Gynecology, Faculty of Medicine, Université Laval
2705 boulevard Laurier, Québec, QC G1V 4G2 (Canada)
E-Mail emmanuel.bujold@crchul.ulaval.ca


 goto top of outline Article Information

Received: November 22, 2011
Accepted after revision: January 17, 2012
Published online: March 21, 2012
Number of Print Pages : 6
Number of Figures : 3, Number of Tables : 2, Number of References : 35


 goto top of outline Publication Details

Fetal Diagnosis and Therapy (Clinical Advances and Basic Research)

Vol. 31, No. 3, Year 2012 (Cover Date: April 2012)

Journal Editor: Gratacós E. (Barcelona)
ISSN: 1015-3837 (Print), eISSN: 1421-9964 (Online)

For additional information: http://www.karger.com/FDT


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.